title: Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Southwest Oncology Group study.
abstract: The prognostic impact of trisomy 8, alone or with other clonal aberrations, was evaluated in 849 patients with previously untreated acute myeloid leukemia (AML) who were registered to 5 Southwest Oncology Group trials. At presentation, 108 (12.7%) patients had +8 in their karyotypes, including 43 (5.1%) patients with +8 as the sole aberration; 307 (36.2%) were normal, and 434 (51.1%) had other cytogenetic abnormalities. Patients with +8 were slightly older (P =.033), had lower WBC (P =.011), and had lower percentages of peripheral blasts (P =.0004) than the patients without +8. Median survival time for all patients with +8 was 9.9 months (95% CI, 6.5-12.5), similar to that of "unfavorable" cytogenetics risk groups (8.3 months; 95% CI, 6.8-9.5.) Patients with +8 had significantly lower peripheral blasts (P =.0002), WBC (P <.0001) counts, and decreased overall survival (OS) than patients with normal cytogenetics (9.9 months vs 15.4 months; P =.006). However, survival of patients with +8 as the sole aberration did not differ significantly from those with normal cytogenetics (P =.36). Thus, the trisomy 8 group as a whole had poor survival, which was largely attributable to worsened outcomes among patients whose trisomy 8 was associated with other unfavorable cytogenetic abnormalities.
authors.affiliation: Wayne State University, Detroit, MI, USA. swolman@pathol.faseb.org
authors.forename: Sandra R
authors.initials: SR
authors.lastname: Wolman
authors.forename: Holly
authors.initials: H
authors.lastname: Gundacker
authors.forename: Frederick R
authors.initials: FR
authors.lastname: Appelbaum
authors.forename: Marilyn L
authors.initials: ML
authors.lastname: Slovak
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics*; D020732:Cytogenetic Analysis; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000453:epidemiology / Q000235:genetics* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012307:Risk Factors; D015206:Southwestern United States; D016019:Survival Analysis; D016896:Treatment Outcome; D014314:Trisomy / Q000473:pathology*